ArticleInternational journal of cancer2017
Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies.
Open access · bronzeAbstract read
In one paragraph
Article in International journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium.Cancer causes & control : CCC · 2019Pooled it
- Differences in overall survival for invasive epithelial ovarian cancer by race and ethnicity: results from the Ovarian Cancer Association Consortium.British journal of cancer · 2026Article
- A Multistate Survival Model to Identify Risk Factors for Lethal Ovarian Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Smoking Cessation and Mortality Risk in Cancer Survivorship: Real-World Data From a National Cancer Institute-Designated Cancer Center.Journal of the National Comprehensive Cancer Network : JNCCN · 2025Observational
- Cellular origins of mucinous ovarian carcinoma.The Journal of pathology · 2025Review
- Cigarette smoking in relation to survival in Black women with ovarian cancer: Evidence from the African American Cancer Epidemiology Study (AACES).Annals of epidemiology · 2025Article
- fRAP 2.0: a community engagement method applied to cervical cancer disparities among Hispanic women.Family medicine and community health · 2024Article
- Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Predictors of residual disease after debulking surgery in advanced stage ovarian cancer.Frontiers in oncology · 2023Article
- Racial disparities in epithelial ovarian cancer survival: An examination of contributing factors in the Ovarian Cancer in Women of African Ancestry consortium.International journal of cancer · 2022Article
- Germline BRCA variants, lifestyle and ovarian cancer survival.Gynecologic oncology · 2022Article
- Reproductive Factors Do Not Influence Survival with Ovarian Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- A Novel Mixed Methods Approach Combining Geospatial Mapping and Qualitative Inquiry to Identify Multilevel Policy Targets: The Focused Rapid Assessment Process (fRAP) Applied to Cancer Survivorship.Journal of mixed methods research · 2022Article
- High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study.Cancer epidemiology · 2022Article
- Smoking and Neuropsychiatric Disease-Associations and Underlying Mechanisms.International journal of molecular sciences · 2021Review
- Identification of Hypoxia Signature to Assess the Tumor Immune Microenvironment and Predict Prognosis in Patients with Ovarian Cancer.International journal of endocrinology · 2021Article
- Prediagnosis and postdiagnosis smoking and survival following diagnosis with ovarian cancer.International journal of cancer · 2020Article
- Association between Cigarette Smoking and Histotype-Specific Epithelial Ovarian Cancer: A Review of Epidemiologic Studies.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019Review
- Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium.International journal of cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
51 authors at 20 institutions in 9 countries.
Camilla PraestegaardVirus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Allan JensenVirus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Signe M JensenStatistics, Bioinformatics and Registry, Danish Cancer Society Research Center, Copenhagen, Denmark.
Thor S S NielsenVirus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Penelope M WebbPopulation Health Department, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Christina M NaglePopulation Health Department, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Anna DeFazioCentre for Cancer Research, The Westmead Millenium Institute for Medical Research, The University of Sydney Westmead, NSW, Australia.
Australian Ovarian Cancer Study GroupPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Estrid HøgdallVirus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Mary Anne RossingProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.
Jennifer A DohertyDepartment of Epidemiology, The Geisel School of Medicine, Dartmouth College, Hanover, NH.
Kristine G WicklundProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.
Marc T GoodmanCancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Francesmary ModugnoDepartment of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Kirsten MoysichDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY.
Roberta B NessSchool of Public Health, The University of Texas, Houston, TX.
Robert EdwardsDepartment of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Keitaro MatsuoDivision of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan.
Satoyo HosonoDivision of Epidemiology and Prevention, Aichi Cancer Center Research institute, Nagoya, Aichi, Japan.
Ellen L GoodeDepartment of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, MN.
Stacey J WinhamDepartment of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
Brooke L FridleyUniversity of Kansas Medical Center, Kansas City, KS.
Daniel W CramerObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA.
Kathryn L TerryObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA.
Joellen M SchildkrautDepartment of Public Health Science, School of Medicine, University of Virginia, Charlottesville, VA.
Andrew BerchuckDepartment of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC.
Elisa V BanderaCancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
Lisa E PaddockNew Jersey Department of Health and Senior Services, Trenton, NJ.
Leon F MassugerDepartment of Gynaecology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Paul PharoahDepartment of Oncology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research laboratory, Cambridge, United Kingdom.
Honglin SongDepartment of Oncology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research laboratory, Cambridge, United Kingdom.
Alice WhittemoreDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, CA.
Valerie McGuireDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, CA.
Weiva SiehDepartments of Population Health Science & Policy and of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.
Joseph RothsteinDepartments of Population Health Science & Policy and of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.
Hoda Anton-CulverDepartment of Epidemiology, Center for Cancer Genetics Research & Prevention, School of Medicine, University of California Irvine, Irvine, CA.
Argyrios ZiogasDepartment of Epidemiology, University of California Irvine, Irvine, CA.
Usha MenonWomen's Cancer, Institute for Women's Health, University College London, London, United Kingdom.
Simon A GaytherCenter for Cancer Prevention and Translational Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Susan J RamusSchool of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia.
Alexandra Gentry-MaharajWomen's Cancer, Institute for Women's Health, University College London, London, United Kingdom.
Anna H WuDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.
Celeste L PearceDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.
Malcolm PikeDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.
Alice W LeeDepartment of Health Science, California State University, Fullerton, CA.
Rebecca SutphenEpidemiology Center, College of Medicine, University of South Florida, Tampa, FL.
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Harvey A RischDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT.
Susanne K KjaerVirus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Ovarian Cancer Association Consortium
Cedars-Sinai Medical Center · USDanish Cancer Society · DKUniversity of Copenhagen · DKUniversity of Southern California · USBrigham and Women's Hospital · USUniversity of California, Irvine · USUniversity of Cambridge · GBAichi Cancer Center · JPDartmouth College · USMayo Clinic · USQIMR Berghofer Medical Research Institute · AURoswell Park Comprehensive Cancer Center · USRutgers, The State University of New Jersey · USUniversität Hamburg · DEUniversity of Pittsburgh · USCalifornia State University, Fullerton · USDuke Medical Center · USGarvan Institute of Medical Research · AUIcahn School of Medicine at Mount Sinai · USNew Jersey Department of Health · US
Funding
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Saul Priceman · 1985 to 2026
$181.4MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Keith L. Knutson · 1985 to 2026
$151.3MTwo-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Christine B. Ambrosone · 1985 to 2026
$116.6MTRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Shridar Ganesan · 1997 to 2026
$94.5MTRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5MYale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI MARCUS W BOSENBERG · 1985 to 2026
$85.0MTranslational Research Support CoreP30ES007048 · NIEHS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROB S MCCONNELL · 1996 to 2026
$46.4MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI SCOTT H KAUFMANN · 2009 to 2026
$37.0MWITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2MNorthern California Cooperative Family Registry for Breast CancerU01CA069417 · NCI · NORTHERN CALIFORNIA CANCER CENTER · PI JOHN, ESTHER M. · 1995 to 2010
$22.4MRPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B., ODUNSI, KUNLE · 2013 to 2025
$19.6MUSC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 1985 to 2009
$18.2MCancer Research UK 10124Cancer Research UK 16561Cancer Research UK C490/A10119Cancer Research UK C490/A10124Department of HealthNCCDPHP CDC HHS U58 DP003931NCI NIH HHS HHSN261201300021CNCI NIH HHS K07 CA080668NCI NIH HHS K07 CA092044NCI NIH HHS K07 CA095666NCI NIH HHS K07 CA143047NCI NIH HHS K22 CA138563NCI NIH HHS N01 CN025403NCI NIH HHS N01 PC067010NCI NIH HHS P01 CA017054NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA016359NCI NIH HHS P30 CA072720NCI NIH HHS P30 CA076292NCI NIH HHS P50 CA105009NCI NIH HHS P50 CA136393NCI NIH HHS P50 CA159981NCI NIH HHS R01 CA054419NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA058860NCI NIH HHS R01 CA074850NCI NIH HHS R01 CA076016NCI NIH HHS R01 CA080742NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA106414NCI NIH HHS R01 CA112523NCI NIH HHS R01 CA122443NCI NIH HHS R01 CA188900NCI NIH HHS R03 CA113148NCI NIH HHS R03 CA115195NCI NIH HHS U01 CA069417NCRR NIH HHS M01 RR000056NIA NIH HHS R01 AG061132NIEHS NIH HHS P30 ES007048
Abstract
Cigarette smoking is associated with an increased risk of developing mucinous ovarian tumors but whether it is associated with ovarian cancer survival overall or for the different histotypes is unestablished. Furthermore, it is unknown whether the association between cigarette smoking and survival differs according to strata of ovarian cancer stage at diagnosis. In a large pooled analysis, we evaluated the association between various measures of cigarette smoking and survival among women with epithelial ovarian cancer. We obtained data from 19 case-control studies in the Ovarian Cancer Association Consortium (OCAC), including 9,114 women diagnosed with ovarian cancer. Cox regression models were used to estimate adjusted study-specific hazard ratios (HRs), which were combined into pooled hazard ratios (pHR) with corresponding 95% confidence intervals (CIs) under random effects models. Overall, 5,149 (57%) women died during a median follow-up period of 7.0 years. Among women diagnosed with ovarian cancer, both current (pHR = 1.17, 95% CI: 1.08-1.28) and former smokers (pHR = 1.10, 95% CI: 1.02-1.18) had worse survival compared with never smoking women. In histotype-stratified analyses, associations were observed for mucinous (current smoking: pHR = 1.91, 95% CI: 1.01-3.65) and serous histotypes (current smoking: pHR = 1.11, 95% CI: 1.00-1.23; former smoking: pHR = 1.12, 95% CI: 1.04-1.20). Further, our results suggested that current smoking has a greater impact on survival among women with localized than disseminated disease. The identification of cigarette smoking as a modifiable factor associated with survival has potential clinical importance as a focus area to improve ovarian cancer prognosis.
Indexed as
AdultAgedAged, 80 and overCarcinoma, Ovarian EpithelialCase-Control StudiesFemaleHumansMiddle AgedNeoplasms, Glandular and EpithelialNicotianaOvarian NeoplasmsProportional Hazards ModelsRisk FactorsSmokingYoung Adultcigarette smokingovarian cancerpooled analysissurvival
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.